Abstract:The cannabinoid receptor 2 (CB2) plays an important role in the immune system. Although a few of GPCRs crystallographic structures have been reported, it is still challenging to obtain functional transmembrane proteins and high resolution X-ray crystal structures, such as for the CB2 receptor. In the present work, we used 10 reported crystal structures of GPCRs which had high sequence identities with CB2 to construct homology-based comparative CB2 models. We applied these 10 models to perform a prescreen by using a training set consisting of 20 CB2 active compounds and 980 compounds randomly selected from the National Cancer Institute (NCI) database. We then utilized the known 170 cannabinoid receptor 1 (CB1) or CB2 selective compounds for further validation. Based on the docking results, we selected one CB2 model (constructed by β1AR) that was most consistent with the known experimental data, revealing that the defined binding pocket in our CB2 model was well-correlated with the training and testing data studies. Importantly, we identified a potential allosteric binding pocket adjacent to the orthosteric ligand-binding site, which is similar to the reported allosteric pocket for sodium ion Na(+) in the A2AAR and the δ-opioid receptor. Our studies in correlation of our data with others suggested that sodium may reduce the binding affinities of endogenous agonists or its analogs to CB2. We performed a series of docking studies to compare the important residues in the binding pockets of CB2 with CB1, including antagonist, agonist, and our CB2 neutral compound (neutral antagonist) XIE35-1001. Then, we carried out 50 ns molecular dynamics (MD) simulations for the CB2 docked with SR144528 and CP55940, respectively. We found that the conformational changes of CB2 upon antagonist/agonist binding were congruent with recent reports of those for other GPCRs. Based on these results, we further examined one known residue, Val113(3.32), and predicted two new residues, Phe183 in ECL2 and Phe281(7.35), that were important for SR144528 and CP55940 binding to CB2. We then performed site-directed mutation experimental study for these residues and validated the predictions by radiometric binding affinity assay.

Comparative Modeling and Evaluation of Leukotriene B4 Receptors for Selective Drug Discovery Towards the Treatment of Inflammatory Diseases

Structural basis of leukotriene B4 receptor 1 activation

Structural diversity of leukotriene G-protein coupled receptors

In Silico Modeling of the Molecular Structure and Binding of Leukotriene A4 into Leukotriene A4 Hydrolase

Discovery of a novel BLT2 antagonist for the treatment of inflammatory airway diseases

Leukotriene B4 receptor 1 (BLT1) activation by leukotriene B4 (LTB4) and E resolvins (RvE1 and RvE2)

Modeling, Molecular Dynamics Simulation, and Mutation Validation for Structure of Cannabinoid Receptor 2 Based on Known Crystal Structures of GPCRs

A homology modeling study toward the understanding of three-dimensional structure and putative pharmacological profile of the G-protein coupled receptor GPR55.

Cross-species amino acids sequence comparison and computational docking of human IL-1Ra and rat IL-1Ra on rat receptor

Integrating Pharmacophore Into Membrane Molecular Dynamics Simulations To Improve Homology Modeling Of G Protein-Coupled Receptors With Ligand Selectivity: A(2a) Adenosine Receptor As An Example

Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex

A unique ligand-steered strategy for CC chemokine receptor 2 homology modeling to facilitate structure-based virtual screening

Structure-based drug design using GPCR homology modeling: toward the discovery of novel selective CysLT2 antagonists.

Exploration of the Binding Modes of Toll‐Like Receptor 4 Competitive Inhibitors: A Combined Ligand‐Based and Target‐Based Approach

Computational modeling of mast cell tryptase family informs selective inhibitor development

Using molecular dynamics for the refinement of atomistic models of GPCRs by homology modeling

Combined Machine Learning and GRID-Independent Molecular Descriptor (GRIND) Models to Probe the Activity Profiles of 5-Lipoxygenase Activating Protein Inhibitors

A Practical Guide to Molecular Docking and Homology Modelling for Medicinal Chemists

Computational Studies of the Binding Modes of Ccr1 Antagonists

Structure based classification for bile salt export pump (BSEP) inhibitors using comparative structural modeling of human BSEP

Structural Features and Ligand Selectivity for 10 Intermediates in the Activation Process of Β2-Adrenergic Receptor